Table I. Ptpn22−/− mice are protected from K/B×N arthritis
RecipientnTreatmentMean Time to Peak (d)Mean Maximal Score (± SD)Time at Peak Intensity (d)Median Clinical Score
WT female975 μl on day 06.28.6 (± 1.9)23.8
ko female975 μl on day 06.85.0 (± 1.9)3.42.3
WT female4100 μl on day 0, 100 μl on day 25.810.25 (± 1.6)48.25
ko female3100 μl on day 0, 100 μl on day 276.0 (± 1.7)3.73.0
WT male6100 μl on day 04.29.8 (± 1.6)2.34.0
ko male6100 μl on day 06.76.5 (± 2.9)3.33.3
  • Irrespective of the gender of the recipient and of disease induction with a single injection or repeat injections with arthritogenic serum, Ptpn22−/− mice were characterized by slower disease progression and reduced peak amplitude.

  • ko, knockout.